Patents by Inventor Vassiliki A. Boussiotis
Vassiliki A. Boussiotis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230331847Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.Type: ApplicationFiled: September 22, 2022Publication date: October 19, 2023Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
-
Patent number: 11492403Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.Type: GrantFiled: April 20, 2018Date of Patent: November 8, 2022Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard CollegeInventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
-
Publication number: 20200115452Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.Type: ApplicationFiled: April 20, 2018Publication date: April 16, 2020Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Straus
-
Patent number: 7700102Abstract: Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 16, 2002Date of Patent: April 20, 2010Assignees: Dana-Farber Cancer Institute, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Kathryn T. Hall, Gordon J. Freeman, Joachim L. Schultze, Vassiliki A. Boussiotis, Lee M. Nadler, Laurence Boumsell, Armand Bensussan
-
Patent number: 7635757Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: January 26, 2006Date of Patent: December 22, 2009Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
Publication number: 20060233795Abstract: Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells are provided. The methods of the invention involve contacting the CD4+ T cells with an agent which modulates a B7-2-induced signal in the CD4+ T cells, such that the Th2-type response is modulated. Methods for either stimulating or inhibiting Th2 type responses are provided by the invention.Type: ApplicationFiled: March 24, 2006Publication date: October 19, 2006Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Lee Nadler -
Publication number: 20060153841Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 26, 2006Publication date: July 13, 2006Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Patent number: 7038013Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 2, 2001Date of Patent: May 2, 2006Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Patent number: 6936704Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 23, 2000Date of Patent: August 30, 2005Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Publication number: 20040037808Abstract: When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy. This invention is based, at least in part, on the discovery that signaling though a common cytokine receptor &ggr; chain (e.g., interleukin-2 receptor, interleukin-4 receptor, interleukin-7 receptor) prevents the induction of T cell anergy. This &ggr; chain has been found to be associated with a JAK kinase having a molecular weight of about 116 kD (as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis) and signaling through the &ggr; chain induces phosphorylation of the JAK kinase. Accordingly, methods for stimulating or inhibiting proliferation by a T cell which expresses a cytokine receptor &ggr; chain are disclosed.Type: ApplicationFiled: June 10, 2003Publication date: February 26, 2004Applicant: Dana-Farber Cancer InstituteInventors: Vassiliki A. Boussiotis, Lee M. Nadler
-
Publication number: 20030158402Abstract: Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferationare disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 16, 2002Publication date: August 21, 2003Applicant: Dana-Farber Cancer InstituteInventors: Kathryn T. Hall, Gordon J. Freeman, Joachim L. Schultze, Vassiliki A. Boussiotis, Lee M. Nadler
-
Patent number: 6576236Abstract: When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy. This invention is based, at least in part, on the discovery that signaling though a common cytokine receptor &ggr; chain (e.g., interleukin-2 receptor, interleukin-4 receptor, interleukin-7 receptor) prevents the induction of T cell anergy. This &ggr; chain has been found to be associated with a JAK kinase having a molecular weight of about 116 kD (as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis) and signaling through the &ggr; chain induces phosphorylation of the JAK kinase. Accordingly, methods for stimulating or inhibiting proliferation by a T cell which expresses a cytokine receptor &ggr; chain are disclosed.Type: GrantFiled: July 1, 1994Date of Patent: June 10, 2003Assignee: Dana Farber Cancer InstituteInventors: Vassiliki A. Boussiotis, Lee M. Nadler
-
Patent number: 6576754Abstract: Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 9, 1995Date of Patent: June 10, 2003Assignee: Dana-Farber Cancer InstituteInventors: Kathryn T. Hall, Gordon J. Freeman, Joachim L. Schultze, Vassiliki A. Boussiotis, Lee M. Nadler
-
Publication number: 20030044416Abstract: Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferationare disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: November 9, 1995Publication date: March 6, 2003Applicant: DANA-FARBER CANCER INSTITUTEInventors: KATHRYN T. HALL, GORDON J. FREEMAN, JOACHIM L. SCHULTZE, VASSILIKI A. BOUSSIOTIS, LEE M. NADLER
-
Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
Publication number: 20020182727Abstract: Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells are provided. The methods of the invention involve contacting the CD4+ T cells with an agent which modulates a B7-2-induced signal in the CD4+T cells, such that the Th2-type response is modulated. Methods for either stimulating or inhibiting Th2 type responses are provided by the invention.Type: ApplicationFiled: March 11, 2002Publication date: December 5, 2002Applicant: Dana-Farber Cancer InstituteInventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Lee M. Nadler -
Patent number: 6451305Abstract: Methods for stimulating a T cell response to a tumor cell in a subject with a tumor which involve modifying the tumor cell to express a CD2 ligand and a CD28 or CTLA4 ligand, are disclosed. Methods wherein the tumor cell is obtained from the subject and modified ex vivo to form a modified tumor cell and then the modified tumor cell is administered to the subject, are also disclosed.Type: GrantFiled: June 1, 1995Date of Patent: September 17, 2002Assignee: Dana-Farber Cancer InstituteInventors: Vassiliki A. Boussiotis, Gordon J. Freeman, Lee M. Nadler
-
Publication number: 20020127201Abstract: When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy. This invention is based, at least in part, on the discovery that signaling though a common cytokine receptor &ggr; chain (e.g., interleukin-2 receptor, interleukin-4 receptor, interleukin-7 receptor, interleukin-15 receptor) prevents the induction of T cell anergy. This &ggr; chain has been found to be associated with a JAK3 kinase having a molecular weight of about 116 kD (as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis) and signaling through the &ggr; chain induces phosphorylation of the JAK3 kinase. Accordingly, methods for stimulating or inhibiting proliferation by a T cell which expresses a cytokine receptor &ggr; chain are disclosed.Type: ApplicationFiled: May 7, 2002Publication date: September 12, 2002Applicant: Dana-Farber Cancer Institute.Inventors: Vassiliki A. Boussiotis, Lee M. Nadler
-
Publication number: 20020102651Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: November 2, 2001Publication date: August 1, 2002Applicant: Dana Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Publication number: 20020051784Abstract: Methods for modulating antigen-specific T cell unresponsiveness which involve inhibiting or stimulating an unresponsive T cell through a cell surface receptor, CD2, are disclosed. Agents which inhibit stimulation of an unresponsive T cell through a CD2 surface receptor are useful therapeutically in situations where it is desirable to inhibit an immune response to an antigen(s), for example in organ or bone marrow transplantation and autoimmune diseases. Methods for reversing T cell unresponsiveness by contacting the T cell with an agent which stimulates the T cell through a CD2 surface receptor are useful therapeutically to stimulate an immune response to an antigen(s). For example, the method is useful to stimulate an anti-tumor response in a subject with a tumor or stimulate a response against a pathogenic agent or increase the efficacy of vaccination.Type: ApplicationFiled: November 28, 2001Publication date: May 2, 2002Applicant: Dana Farber Cancer instituteInventors: Vassiliki A. Boussiotis, Gordon J. Freeman, Lee M. Nadler